Can a smart immune cell with a kill switch beat tough lymphomas?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Procurement Inclusion Criteria: Participants must meet the protocol-defined procurement eligibility criteria before collection of peripheral blood mononuclear cells for manufacture of the investigational product, including: 1. Diagnosis of relapsed or refractory Hodgkin lymphoma or non-Hodgkin lymphoma. 2. CD30 positive tumor (can be pending at this time) as assayed in a CLIA certified Pathology Laboratory. 3. Age 16 to 75 years. 4. Hemoglobin ≥7.0(may be transfused value). 5. Karnofsky or Lansky score of \> 60% 6. Informed consent explained to, understood by and signed by patient or guardian. Patient or guardian given copy of informed consent. Procurement Exclusion Criteria: 1. Active HIV or HTLV infection (testing may be pending at procurement). 2. Active bacterial, fungal, or viral infection. \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Treatment Inclusion Criteria: Participants with a successfully manufactured product must continue to satisfy the protocol-defined treatment eligibility criteria before receiving study treatment, including: 1. Diagnosis and clinical course falling into one of the following categories: * Hodgkin lymphoma * CD30+ aggressive B-cell lymphoma * ALK-negative anaplastic T cell lymphoma or other peripheral T- cell lymphoma * ALK-positive anaplastic T cell lymphoma 2. CD30 expression confirmed in a CLIA-certified laboratory. Recovered from all acute non-hematologic toxic effects of all prior chemotherapy 3. Age 16 to 75 years. 4. Bilirubin ≤ 2 times the upper limit of normal (except for Gilbert syndrome, where the criteria will be Bilirubin ≤ 3 times the upper limit of normal). 5. AST ˂ 3 times the upper limit of normal 6. Estimated GFR \> 50 mL/min 7. Pulse oximetry of \> 90% on room air 8. Karnofsky or Lansky score of \> 60% 9. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after study is concluded. Male partner should use a condom 10. Informed consent explained to, understood by and signed by patient/guardian. Patient/Guardian given copy of informed consent. Treatment Exclusion Criteria: 1. Received an investigational cell therapy or vaccine within the past 6 weeks. 2. Received an investigational small molecule within the past 2 weeks. 3. Received anti-CD30 antibody-based therapy within the previous 4 weeks. 4. History of hypersensitivity reactions to murine protein-containing products 5. Pregnancy or breastfeeding. 6. Tumor in a location where enlargement could cause airway obstruction (determined at the investigators' discretion) 7. Current use of systemic corticosteroids at a dose equivalent to higher than 10 mg/day of prednisone. 8. Active significant, uncontrolled bacterial, viral or fungal infection. 9. Symptomatic cardiac disease (NYHA Class III or IV disease).